Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$28.09
$1.42(5.06%)
At close: 4:00 PM EDT
$28.09
$1.42(5.06%)
Day’s Range― - ―
52-Week Range$13.74 - $65.30
Previous CloseN/A
Volume4.79M
Average Volume (3M)15.98M
Market Cap
$6.57B
Enterprise Value$8.74K
Total Cash (Recent Filing)$841.05M
Total Debt (Recent Filing)$1.55B
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Nov 09, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume14,448,064
30 Day Avg. Volume15,981,831
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.75Price Target Upside20.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$2.93B
Bulls Say, Bears Say
Bulls Say
Strong Revenue & Subscriber GrowthSustained high revenue growth and rapid subscriber adds indicate durable demand for the DTC telehealth model. Large recurring subscriber base improves lifetime value, supports cross-sell of specialties, and creates a predictable revenue stream that underpins multi‑period scale and product expansion.
Positive Operating Cash Flow & Free Cash FlowGenerating positive operating and free cash flow despite a TTM GAAP loss shows underlying cash economics and ability to self-fund growth. This durable cash generation reduces reliance on equity dilution and supports reinvestment in marketing, fulfillment, and AI efficiency programs.
Meaningful International Scale From Eucalyptus DealAcquiring Eucalyptus materially diversifies geographic exposure and regulatory know‑how, accelerating international revenue scale. Broader footprint improves addressable market, local market expertise, and data/network effects that can lower customer acquisition costs and sustain long-term growth.
Bears Say
Rapidly Rising LeverageMaterial increase in debt materially reduces financial flexibility and raises refinancing and interest risks. High leverage amplifies downside if profitability or cash flow weaken, constrains strategic optionality, and can force capital allocation toward debt service rather than growth investments.
Gross Margin Compression From Mix ShiftA strategic shift into lower‑margin branded weight‑loss products and international sales is compressing unit economics. Unless offset by scale efficiencies or higher prices, the structural mix change can permanently lower gross margins and pressure operating profitability over the medium term.
Regulatory And Legal UncertaintyActive FTC litigation and dependence on FDA rulemaking for peptides introduce prolonged legal and timing risk. These regulatory headwinds can delay product launches, increase compliance costs, and create uncertainty around growth prospects and margins for several quarters to years.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $65.30 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $6.57B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 84 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.32.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is 0.07.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 224,935,790 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.966%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.75 (20.15% Upside)
$33.75 (20.15% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 74%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $342.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is a consumer-focused digital health company that provides access to telehealth visits and prescription and non-prescription treatments through its online platforms and affiliated brands (Hims and Hers). The company focuses on conditions typically addressed in outpatient settings—such as dermatology, sexual health, mental health, and other everyday health needs—combining virtual clinical intake/consultation workflows with fulfillment of medications and products directly to customers.
HIMS Company Deck
HIMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$33.75
▲(20.15% Upside)
Technical Analysis
Ownership Overview
5.16% Insiders
14.65% Mutual Funds
11.72% Other Institutional Investors
47.75% Public Companies and Individual Investors